US20100227830A1 - Use of escin - Google Patents
Use of escin Download PDFInfo
- Publication number
- US20100227830A1 US20100227830A1 US12/376,419 US37641907A US2010227830A1 US 20100227830 A1 US20100227830 A1 US 20100227830A1 US 37641907 A US37641907 A US 37641907A US 2010227830 A1 US2010227830 A1 US 2010227830A1
- Authority
- US
- United States
- Prior art keywords
- escin
- preparation
- allergy
- disease
- granulocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention relates to the field of immunology.
- An allergy can refer to several kinds of unwanted immune reactions including Type I and Type III hypersensitivities.
- Leukocytes consist of different cell types that all origin from stem cells in the bone marrow. They are further subdivided into lymphocytes (T-cells, B-cells, natural killer cells), myeloid cells (monocytes, macrophages) and granulocytes (eosinophils, neutrophils, and basophils).
- Mast cells are closely related to basophils and are often regarded as the tissue residing type of a granulocyte.
- Granulocytes are defined as eosinophils, neutrophils, basophils, and mast cells.
- Granulocytes are part of the innate immune response, an unspecific reaction towards pathogens, such as bacteria. This is also reflected by the fact that lipopolysacharide (LPS, component of bacterial cell wall) activation of granulocytes results in a pronounced release of cytokines, such as tumour necrosis factor alpha (TNF-alpha).
- cytokines such as tumour necrosis factor alpha (TNF-alpha).
- Activation of granulocytes with either IgE- (type I allergy) or IgG complexes (type III allergy) results in a strong and fast reaction against otherwise innocuous agents (pollen, food, reactions against own structures and tissues such in autoimmune diseases).
- Mast cells and basophils are the cellular basis for type I allergies (IgE-mediated allergies via the Fc ⁇ RI), neutrophils are involved in type III allergies (immune complex mediated reactions, via the Fc ⁇ RIII) including autoimmune diseases such as psoriasis, arthritis, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE), and contributes to other autoimmune diseases such as rheumatoid arthritis (RA), type I diabetes and multiple sclerosis. Allergies of both types can result in symptoms as benign as a runny nose, to severe chronic diseases and also to life-threatening anaphylactic shock or septic shock.
- ITP immune thrombocytopenia
- AHA autoimmune hemolytic anemia
- SLE systemic lupus erythematosus
- RA rheumatoid arthritis
- Allergies of both types can result in symptoms as benign as a run
- Type I allergies are commonly treated by corticosteroids (cortisone), anti-histamines, ephinephrine, theophylline or mast cell stabilizers. These compounds block the action of allergic mediators, preventing activation of cells and degranulation processes. These drugs help alleviate the symptoms of allergy but play little role in chronic alleviation of the disorder. All of these therapeutical classes have quite substantial side-effects especially after long-term use. Allergies have an increasing incidence in the western hemisphere with about 20% of the population being affected now. A review and recommendation for treatment of allergic rhinitis has been published by the British National Prescribing Center: MeReC Bulletin Volume 9, Number 3, 1998.
- Another treatment form of allergies involves the intravenous injection of monoclonal anti-IgE antibodies.
- Hyposensitization is a form of immunotherapy where the patient is gradually vaccinated against progressively larger doses of the allergen in question. This can either reduce the severity or eliminate hypersensitivity altogether. It relies on the progressive skewing of IgG production, as opposed to the excessive IgE production seen in hypersensitivity type I cases.
- Allergic diseases type III are commonly treated by steroids, non-steroid anti-inflammatory drugs, methotrexate, and TNF-alpha blocker (receptor analogs or antibodies).
- Some autoimmune diseases such as psoriasis or blistering diseases are further complicated by secondary infections of the skin.
- secondary infections that are the result of chronic disorder such as psoriasis are often left untreated.
- the inflammatory process is worsened and the disease progresses.
- there is still a strong medical need as many of these substances are not suited for a chronic application or the treatment is too expensive for broad use (biological substances).
- Psoriasis or rheumatoid arthritis belong to the most common autoimmune diseases with 1-2% of the population being affected.
- Sirtori discloses an anti-inflammatory effect of aescin which is effected by the reduction of vascular permeability which can reduce the density of leucocytes in affected tissue.
- Dattner (Dermatologic Therapy 16 (2003): 106-113) discusses horse chestnuts in the field of herbal medicine with an anti-inflammatory and vasoprotective effect. An elastase-inhibitory activity is attributed to escin.
- a goal of the present invention is to provide further medications, which are effective against diverse immunological diseases that are based on a hyper-response of granulocytes.
- the present invention provides the use of escin for the manufacture of a pharmaceutical preparation (or a medicament) for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.
- Leukocytes such as granulocytes play a role in almost all diseases as the body's defense system. Some symptoms of any disease may be related to the direct effector functions of the granulocytes.
- the term “diseases caused or mediated by granulocytes” is to be understood in the context of the origin of the disease and not only the symptoms of the disease.
- the diseases to be treated by the pharmaceutical preparation are therefore related to an aberrant or excessive function of granulocytes.
- the present invention relates to the use of escin for the manufacture of pharmaceutical preparation for the treatment of a disease, wherein the origin of the disease is mediated or caused by activated granulocytes.
- the granulocytes are hyperactivated. This excessive activation can lead to severe systemic adverse effects like shock syndromes, e.g. allergic shock.
- the granulocytes, as defined herein, are preferably independently selected from any of eosinophils, neutrophils, basophils and mast cells.
- the present invention discloses the treatment of a type I or type III allergy, autoimmune diseases or septic shock with a pharmaceutical preparation comprising escin.
- Escin also called aescin
- Escin is a triterpene saponin mixture extracted from the seed of chestnut. It is a component of several pharmaceuticals on the market (in Austria: Reparil from Madaus, Opino from Wabosan, Venosin from Astellas and several more). Often the products contain additional pharmaceutically active compounds such as diethylammoniumsalicylic acid, Buphenin and essential oils. Its primary indication is venous insufficiency based on the inhibitory potential of escin on lysosomal proteins and subsequently the reduced permeability of capillaries.
- HCE horse-chestnut extracts
- HCSE horse-chestnut seeds extracts
- Escin is also known as an anti-inflammatory substance, but mainly due to its inhibition of edema. An inhibition of an inflammatory response at cellular level has not been described so far.
- a detailed review of the use of escin and horse chestnut extracts can be found in: Tiffany at al., Journal of Herbal Pharmacotherapy, Vol. 2 (1) 2002:71-85.
- the antioedematous mechanism of ⁇ -escin is still unknown, specially at the molecular level. Besides some speculations about the mechanism of action of this molecule exists, clearly further research is needed.
- NF- ⁇ B nuclear factor-KB
- TNF-alpha tumor necrosis factor- ⁇
- escin has proinflammatory effects.
- it is used as adjuvant in several pharmaceutical preparations (U.S. Pat. No. 7,049,063, U.S. Pat. No. 7,033,827, U.S. Pat. No. 6,943,236, U.S. Pat. No. 6,894,146, U.S. Pat. No. 6,858,204, U.S. Pat. No. 6,800,746, U.S. Pat. No. 6,759,515, U.S. Pat. No. 6,630,305, U.S. Pat. No. 6,509,448, U.S. Pat. No. 6,504,010).
- An adjuvant is an agent, which, while not having any specific antigenic effect in itself, may stimulate the immune system, increasing the response to a vaccine.
- escin has in certain conditions also immunostimmulatory uses.
- an allergy can be treated with escin at a level prior to the stimulation of the immune system.
- IgE/antigen complexes would provoke TNF-alpha release.
- mast cell activation and TNF-alpha release was also inhibited by escin in mast cells which do not rely on the NF- ⁇ B pathway. The treatment with escin results in a selective anti-allergic effect of a different pathway.
- escin can successfully be used in the treatment of allergic diseases and more broadly as inhibitor of activated granulocytes exemplified by an LPS induced shock reaction.
- Escin is for example able to reduce the allergic reaction followed by a stimulus of a complex of Immunoglobulin E (IgE) and the corresponding antigen in vitro.
- Escin inhibits dose-dependently an LPS-mediated release of TNF-alpha in primary human blood.
- escin dramatically reduces the effect of an immunological shock in an in vivo model and was effectively used to treat an ongoing allergic reaction in a patient suffering from uticaria pigmentosa.
- Lymphocytes as exemplified by the human T-cell line Jurkat or myeloid cells as exemplified by the murine monocytic cell line DC18 were not inhibited by escin after stimulation (release of either IL-2 or TNF-alpha respectively). Contrary to previous assumptions (Xiao et al., supra) of molecular targets of escin the anti-allergic effect of escin is independent of NF- ⁇ B. According to the present invention it was found that escin had still an anti-allergic effect in NF- ⁇ B pathway independent mast cells (CFTL12).
- the pharmaceutical preparation to be used according to the present invention contains escin as the only granulocyte-inhibiting component, preferably as the only pharmaceutically active agent.
- the allergic disease is a chronic disease or an unwanted hyper-reaction of granulocytes.
- Escin containing products have been on the market since many years and have an excellent safety profile. Therefore the use of escin either alone or in combination with other drugs is an attractive option for chronic patients.
- the allergic disease is a type I or III allergy, preferably mediated by myeloid cells or granulocytes, or an unwanted reaction of granulocytes.
- the medicament is preferably used to treat an allergic disease selected from any one of allergic rhinitis, Urticaria pigmentosa, atopic dermatitis, allergic asthma, food allergy, allergic conjunctivitis, allergy of the intestinal or uro-genital tract and an allergy of the ears.
- the medicament is preferably used to treat type III allergic diseases or other autoimmune disorders, such as psoriasis, arthritis, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type I diabetes and multiple sclerosis.
- the medicament is preferably used to treat skin diseases with an enhanced activation of granulocytes also including diseases complicated by secondary bacterial infections.
- the pharmaceutical preparation is in form of a preparation for topical or mucosal use, preferably skin lotions, cremes, powders, sprays or gargle solutions.
- the escin preparation is especially suitable for topical application to treat skin or mucosal symptoms of the granulocyte mediated disease such as inflammation. But also systemic, e.g. parenteral or oral (also for specific mucosal treatment), is possible.
- the preparation is in form for oral intake, preferably in form of pastilles, tablets, gums, lozenges, powders or drinking solutions.
- Systemic distribution of escin is especially preferred in cases with systemic granulocyte activation such as an anaphylactic shock or septic shock.
- the preparation may also comprise pharmaceutical carriers, excipients, preferably polymeric excipients, or additives.
- carrier refers to a diluent, e.g. water, saline, excipient, or vehicle with which the composition can be administered.
- the carriers or additives in the pharmaceutical composition may comprise SiO 2 , TiO 2 , a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatine, starch, lactose or lactose monohydrate, alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin.
- the preparation comprises buffers or pH adjusting agents, e.g.
- Escin in the form of a pharmaceutically acceptable salt for example sodium salt may also be used.
- Other pharmaceutically acceptable salts include, among others, potassium, lithium and ammonium salts.
- Preferred excipients are polymers, especially cellulose and cellulose derivatives.
- escin is in doses between 0.01 mg per kg of a patient and 500 mg/kg, preferably between 0.1 mg/kg and 100 mg/kg, most preferred between 1 mg/kg and 40 mg/kg.
- the present invention also provides the use of the pharmaceutical preparations.
- the administration of the preparation is not limited to administrations at the same time of an allergic reaction but can also be used before or after the reaction, e.g. for prophylactic treatment, i.e. a treatment before an expected exposure to an allergen to reduce the force of the reaction.
- FIG. 1 Inhibition of TNF-alpha production of LPS-stimulated human blood cells.
- Human blood was incubated with the indicated concentrations of escin.
- Cells were stimulated with 100 ng/ml LPS (Sigma) and the TNF-alpha in the supernatant was determined with a commercial ELISA Kit (Bender-Med-Systems) after 18 hours of stimulus.
- the x-axis gives the concentrations of escin in ⁇ g/ml
- the y-axis gives the concentration of TNF-alpha in pg/ml.
- FIG. 2 Inhibition of TNF-alpha production from IgE/antigen stimulated mast cells.
- CFTL12 Mast cells were incubated with concentrations ranging from 3.1 ⁇ M to 0.03 ⁇ M ⁇ -escin and 0.3 ⁇ M Dexamethasone respectively. 60 minutes later cells were stimulated with an IgE/antigen complex. Cells were incubated at 37° C. for 6 hours and TNF-alpha in the supernatant was determined by a commercial mouse TNF-alpha ELISA (Bender-Med-Systems). Error bars indicate the standard deviation between 4 independent wells.
- FIG. 4 Symptoms score of a patient with uticaria pigmentosa: A 49 year old patient with uticaria pigmentosa was treated on affected areas of both legs with a gel containing 1.5% escin. The score of symptoms for each area was recorded and documented by digital photography. Treatment for the left leg started at point 0. Diamonds indicate the score of the left leg. Due to the surprising fast response of the left leg the treatment of the right leg was initiated after one hour (quarters). A small area of the skin was left untreated (triangles). X-axis gives the time-points after treatment initiation in hours;
- Escin is Active against LPS Induced TNF-Alpha Release
- TNF-alpha is a mediator that is central in an inflammatory process as observed during infections, and autoimmune diseases. It is released by white blood cells, endothelium and several other tissues in the course of damage, e.g. by infection but also during an allergic reaction. Its release is stimulated by several other mediators, such as interleukin 1 and bacterial endotoxin. Cell based assays using human primary blood cells stimulated with lipopolysaccharide demonstrated that escin dose-dependently inhibits TNF-alpha release ( FIG. 1 ).
- Application of escin reduces the release of this mediator in a dose dependent manner.
- TNF-induction in mice administration of lipopolysaccharide is a well established model for fast immunological reactions and a model for septic shock. As shown in FIG. 3 the treatment of mice with 15 mg/kg of escin reduces the TNF-alpha level to 30%.
- a patient diagnosed with uticaria pigmentosa a disease that is characterized by unspecific allergic reactions caused by an overreaction of mast cells.
- the 49 year old female patient had a history of allergic reactions mainly of the skin and in some cases systemic manifestations that were treated with antihistamines and corticosteroids.
- Prior treatment a strong allergic reaction was ongoing on the skin of large areas of both legs and hands. The patient reported itching and pain of the skin. Clearly the inflammation of the skin was visible.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
Description
- The present invention relates to the field of immunology.
- An allergy can refer to several kinds of unwanted immune reactions including Type I and Type III hypersensitivities. In both types granulocytes, a subset of leukocytes, are involved in the pathogenesis of these diseases. Leukocytes consist of different cell types that all origin from stem cells in the bone marrow. They are further subdivided into lymphocytes (T-cells, B-cells, natural killer cells), myeloid cells (monocytes, macrophages) and granulocytes (eosinophils, neutrophils, and basophils). Mast cells are closely related to basophils and are often regarded as the tissue residing type of a granulocyte. Therefore, in the following granulocytes are defined as eosinophils, neutrophils, basophils, and mast cells. Granulocytes are part of the innate immune response, an unspecific reaction towards pathogens, such as bacteria. This is also reflected by the fact that lipopolysacharide (LPS, component of bacterial cell wall) activation of granulocytes results in a pronounced release of cytokines, such as tumour necrosis factor alpha (TNF-alpha). Activation of granulocytes with either IgE- (type I allergy) or IgG complexes (type III allergy), results in a strong and fast reaction against otherwise innocuous agents (pollen, food, reactions against own structures and tissues such in autoimmune diseases). Mast cells and basophils are the cellular basis for type I allergies (IgE-mediated allergies via the FcεRI), neutrophils are involved in type III allergies (immune complex mediated reactions, via the FcγRIII) including autoimmune diseases such as psoriasis, arthritis, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE), and contributes to other autoimmune diseases such as rheumatoid arthritis (RA), type I diabetes and multiple sclerosis. Allergies of both types can result in symptoms as benign as a runny nose, to severe chronic diseases and also to life-threatening anaphylactic shock or septic shock.
- Type I allergies are commonly treated by corticosteroids (cortisone), anti-histamines, ephinephrine, theophylline or mast cell stabilizers. These compounds block the action of allergic mediators, preventing activation of cells and degranulation processes. These drugs help alleviate the symptoms of allergy but play little role in chronic alleviation of the disorder. All of these therapeutical classes have quite substantial side-effects especially after long-term use. Allergies have an increasing incidence in the western hemisphere with about 20% of the population being affected now. A review and recommendation for treatment of allergic rhinitis has been published by the British National Prescribing Center: MeReC Bulletin
Volume 9,Number 3, 1998. Another treatment form of allergies involves the intravenous injection of monoclonal anti-IgE antibodies. Hyposensitization is a form of immunotherapy where the patient is gradually vaccinated against progressively larger doses of the allergen in question. This can either reduce the severity or eliminate hypersensitivity altogether. It relies on the progressive skewing of IgG production, as opposed to the excessive IgE production seen in hypersensitivity type I cases. Allergic diseases type III are commonly treated by steroids, non-steroid anti-inflammatory drugs, methotrexate, and TNF-alpha blocker (receptor analogs or antibodies). - Some autoimmune diseases such as psoriasis or blistering diseases are further complicated by secondary infections of the skin. In contrast to acute injuries of the skin, where antibiotics are usually applied, secondary infections that are the result of chronic disorder such as psoriasis are often left untreated. As a consequence the inflammatory process is worsened and the disease progresses. In both types of hypersensitivities, however, there is still a strong medical need as many of these substances are not suited for a chronic application or the treatment is too expensive for broad use (biological substances). Psoriasis or rheumatoid arthritis belong to the most common autoimmune diseases with 1-2% of the population being affected.
- Sirtori (Pharmacological Research 44 (3) (2001): 183-193) discloses an anti-inflammatory effect of aescin which is effected by the reduction of vascular permeability which can reduce the density of leucocytes in affected tissue.
- Matsuda et al. (Bioorganic & Medicinal Chemistry Letters 7 (13) (1997): 1611-1616) mention an antiinflammatory effect of isolated escin compounds from horse chestnut which is based on vascular constriction measured through an anti-swelling effect in carragenin induced oedemas in rats.
- Dattner (Dermatologic Therapy 16 (2003): 106-113) discusses horse chestnuts in the field of herbal medicine with an anti-inflammatory and vasoprotective effect. An elastase-inhibitory activity is attributed to escin.
- A goal of the present invention is to provide further medications, which are effective against diverse immunological diseases that are based on a hyper-response of granulocytes.
- The present invention provides the use of escin for the manufacture of a pharmaceutical preparation (or a medicament) for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock. Leukocytes such as granulocytes play a role in almost all diseases as the body's defense system. Some symptoms of any disease may be related to the direct effector functions of the granulocytes. The term “diseases caused or mediated by granulocytes” is to be understood in the context of the origin of the disease and not only the symptoms of the disease. The diseases to be treated by the pharmaceutical preparation are therefore related to an aberrant or excessive function of granulocytes. Allergies are caused by contact to an allergen (external or internal) which mediates an excessive granulocyte reaction which can be considered as the cause of the disease since the allergen by itself would be harmless. Therefore the present invention relates to the use of escin for the manufacture of pharmaceutical preparation for the treatment of a disease, wherein the origin of the disease is mediated or caused by activated granulocytes.
- Also provided is escin for the treatment (or prevention, prophylactic treatment) of diseases mediated or caused by activated granulocytes or for the treatment (or prevention) of a disease, wherein the origin of the disease is mediated or caused by activated granulocytes. In particular embodiments this does not extend to the treatment of inflammation or of oedemas. Prevention should not be interpreted to an absolute success in the sense that a patient can never develop an associated disease but to the reduction of the chance of developing the disease in a prophylactic treatment.
- In particular embodiments the granulocytes are hyperactivated. This excessive activation can lead to severe systemic adverse effects like shock syndromes, e.g. allergic shock. The granulocytes, as defined herein, are preferably independently selected from any of eosinophils, neutrophils, basophils and mast cells.
- In a special aspect the present invention discloses the treatment of a type I or type III allergy, autoimmune diseases or septic shock with a pharmaceutical preparation comprising escin.
- Escin, also called aescin, is a triterpene saponin mixture extracted from the seed of chestnut. It is a component of several pharmaceuticals on the market (in Austria: Reparil from Madaus, Opino from Wabosan, Venosin from Astellas and several more). Often the products contain additional pharmaceutically active compounds such as diethylammoniumsalicylic acid, Buphenin and essential oils. Its primary indication is venous insufficiency based on the inhibitory potential of escin on lysosomal proteins and subsequently the reduced permeability of capillaries. Their anti-inflammatory, anti-oedematous, and venotonic properties, horse-chestnut extracts (HCE) or horse-chestnut seeds extracts (HCSE), standardised to escin, have been studied extensively in preclinical models of CVI and in patients with the disease. A comprehensive overview of the current knowledge on escin as well as the chemical structures of escin has been compiled by Sirtori, Pharmacological Research, Vol. 44 (3) 2001:183-193; the review includes extensive data on the mechanism of action and on the clinical properties of the drug. According to this document beta-escin is the active component of the mixture and is the molecular form present in major available pharmaceutical products. Beta-escin is the preferred form of escin according to the present invention. In addition products containing escin are licensed against traumatic injuries, edema (including edema of the brain), hematoma, bruises, sprain, tendosynovitis, and pain of the spine. Escin is also known as an anti-inflammatory substance, but mainly due to its inhibition of edema. An inhibition of an inflammatory response at cellular level has not been described so far. A detailed review of the use of escin and horse chestnut extracts can be found in: Tiffany at al., Journal of Herbal Pharmacotherapy, Vol. 2 (1) 2002:71-85. Also, the antioedematous mechanism of β-escin is still unknown, specially at the molecular level. Besides some speculations about the mechanism of action of this molecule exists, clearly further research is needed.
- Recently effects of β-escin on the expression of nuclear factor-KB (NF-κB) and tumor necrosis factor-α (TNF-alpha) after traumatic brain injury in rats was studied (Xiao et al., J Zhejiang Univ SCI 2005 6B (1):28 28-32). The authors found a significant reduction of NF-κB expression level in tissue after traumatic brain injury in rats supporting their claim that escin might be useful in patients with traumatic brain injury. It was found that escin can inhibit NF-κB, itself an activator of proinflammatory TNF-alpha.
- According to other sources escin has proinflammatory effects. For example it is used as adjuvant in several pharmaceutical preparations (U.S. Pat. No. 7,049,063, U.S. Pat. No. 7,033,827, U.S. Pat. No. 6,943,236, U.S. Pat. No. 6,894,146, U.S. Pat. No. 6,858,204, U.S. Pat. No. 6,800,746, U.S. Pat. No. 6,759,515, U.S. Pat. No. 6,630,305, U.S. Pat. No. 6,509,448, U.S. Pat. No. 6,504,010). An adjuvant is an agent, which, while not having any specific antigenic effect in itself, may stimulate the immune system, increasing the response to a vaccine. Thus escin has in certain conditions also immunostimmulatory uses.
- Instead of treating the symptoms of an allergy (i.e. treating the edema formation or itch) it was surprisingly found that an allergy can be treated with escin at a level prior to the stimulation of the immune system. In mast cells IgE/antigen complexes would provoke TNF-alpha release. Surprisingly mast cell activation (and TNF-alpha release) was also inhibited by escin in mast cells which do not rely on the NF-κB pathway. The treatment with escin results in a selective anti-allergic effect of a different pathway.
- Herein it was shown for the first time that escin can successfully be used in the treatment of allergic diseases and more broadly as inhibitor of activated granulocytes exemplified by an LPS induced shock reaction. Escin is for example able to reduce the allergic reaction followed by a stimulus of a complex of Immunoglobulin E (IgE) and the corresponding antigen in vitro. Escin inhibits dose-dependently an LPS-mediated release of TNF-alpha in primary human blood. Furthermore escin dramatically reduces the effect of an immunological shock in an in vivo model and was effectively used to treat an ongoing allergic reaction in a patient suffering from uticaria pigmentosa. Lymphocytes as exemplified by the human T-cell line Jurkat or myeloid cells as exemplified by the murine monocytic cell line DC18 were not inhibited by escin after stimulation (release of either IL-2 or TNF-alpha respectively). Contrary to previous assumptions (Xiao et al., supra) of molecular targets of escin the anti-allergic effect of escin is independent of NF-κB. According to the present invention it was found that escin had still an anti-allergic effect in NF-κB pathway independent mast cells (CFTL12). According to a preferred embodiment the pharmaceutical preparation to be used according to the present invention contains escin as the only granulocyte-inhibiting component, preferably as the only pharmaceutically active agent.
- Preferably the allergic disease is a chronic disease or an unwanted hyper-reaction of granulocytes. Escin containing products have been on the market since many years and have an excellent safety profile. Therefore the use of escin either alone or in combination with other drugs is an attractive option for chronic patients.
- In a special embodiment the allergic disease is a type I or III allergy, preferably mediated by myeloid cells or granulocytes, or an unwanted reaction of granulocytes.
- In further embodiments the medicament is preferably used to treat an allergic disease selected from any one of allergic rhinitis, Urticaria pigmentosa, atopic dermatitis, allergic asthma, food allergy, allergic conjunctivitis, allergy of the intestinal or uro-genital tract and an allergy of the ears. In addition, the medicament is preferably used to treat type III allergic diseases or other autoimmune disorders, such as psoriasis, arthritis, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type I diabetes and multiple sclerosis.
- In further embodiments the medicament is preferably used to treat skin diseases with an enhanced activation of granulocytes also including diseases complicated by secondary bacterial infections.
- Preferably the pharmaceutical preparation is in form of a preparation for topical or mucosal use, preferably skin lotions, cremes, powders, sprays or gargle solutions. The escin preparation is especially suitable for topical application to treat skin or mucosal symptoms of the granulocyte mediated disease such as inflammation. But also systemic, e.g. parenteral or oral (also for specific mucosal treatment), is possible.
- In another embodiment the preparation is in form for oral intake, preferably in form of pastilles, tablets, gums, lozenges, powders or drinking solutions. Systemic distribution of escin is especially preferred in cases with systemic granulocyte activation such as an anaphylactic shock or septic shock.
- The preparation may also comprise pharmaceutical carriers, excipients, preferably polymeric excipients, or additives. The term “carrier” refers to a diluent, e.g. water, saline, excipient, or vehicle with which the composition can be administered. For a solid or fluid composition the carriers or additives in the pharmaceutical composition may comprise SiO2, TiO2, a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatine, starch, lactose or lactose monohydrate, alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin. Preferably the preparation comprises buffers or pH adjusting agents, e.g. selected from citric acid, acetic acid, fumaric acid, hydrochloric acid, malic acid, nitric acid, phosphoric acid, propionic acid, sulfuric acid, tartaric acid, or combinations thereof. Escin in the form of a pharmaceutically acceptable salt, for example sodium salt may also be used. Other pharmaceutically acceptable salts include, among others, potassium, lithium and ammonium salts. Preferred excipients are polymers, especially cellulose and cellulose derivatives.
- Preferably escin is in doses between 0.01 mg per kg of a patient and 500 mg/kg, preferably between 0.1 mg/kg and 100 mg/kg, most preferred between 1 mg/kg and 40 mg/kg. The present invention also provides the use of the pharmaceutical preparations. The administration of the preparation is not limited to administrations at the same time of an allergic reaction but can also be used before or after the reaction, e.g. for prophylactic treatment, i.e. a treatment before an expected exposure to an allergen to reduce the force of the reaction.
- The present invention is further illustrated by the following figures and examples, without being limited thereto.
-
FIG. 1 : Inhibition of TNF-alpha production of LPS-stimulated human blood cells. Human blood was incubated with the indicated concentrations of escin. Cells were stimulated with 100 ng/ml LPS (Sigma) and the TNF-alpha in the supernatant was determined with a commercial ELISA Kit (Bender-Med-Systems) after 18 hours of stimulus. The x-axis gives the concentrations of escin in μg/ml, the y-axis gives the concentration of TNF-alpha in pg/ml. -
FIG. 2 : Inhibition of TNF-alpha production from IgE/antigen stimulated mast cells. CFTL12 Mast cells were incubated with concentrations ranging from 3.1 μM to 0.03 μM β-escin and 0.3 μM Dexamethasone respectively. 60 minutes later cells were stimulated with an IgE/antigen complex. Cells were incubated at 37° C. for 6 hours and TNF-alpha in the supernatant was determined by a commercial mouse TNF-alpha ELISA (Bender-Med-Systems). Error bars indicate the standard deviation between 4 independent wells. 1, dexamethasone; 2, non-stimulated; 3, IgE/Antigen stimulated; 4, 3.1 μM escin; 5, 1 μM escin; 6, 0.31 μM escin; 7, 0.1 μM escin; 8, 0.031 μM escin; 1, and 4-8 were stimulated with IgE/Antigen; y-axis gives the concentration of TNF-alpha in pg/ml; -
FIG. 3 : Balb/c mice (n=8) were treated with 15 mg/kg lipopolysaccharide (Sigma). Mice were simultaneously treated with a single dose of 15 mg/kg β-escin. 1 hour after treatment mice were sacrificed and serum was obtained. Levels of TNF-alpha were determined by using a commercial ELISA-Kit (Bender-Med-Systems). The y-axis reflects the amount of TNF-alpha in mouse serum in ng/ml.Bar 1 indicates the vehicle treated mice andbar 2 shows the result of mice treated with escin. -
FIG. 4 : Symptoms score of a patient with uticaria pigmentosa: A 49 year old patient with uticaria pigmentosa was treated on affected areas of both legs with a gel containing 1.5% escin. The score of symptoms for each area was recorded and documented by digital photography. Treatment for the left leg started atpoint 0. Diamonds indicate the score of the left leg. Due to the surprising fast response of the left leg the treatment of the right leg was initiated after one hour (quarters). A small area of the skin was left untreated (triangles). X-axis gives the time-points after treatment initiation in hours; - TNF-alpha is a mediator that is central in an inflammatory process as observed during infections, and autoimmune diseases. It is released by white blood cells, endothelium and several other tissues in the course of damage, e.g. by infection but also during an allergic reaction. Its release is stimulated by several other mediators, such as
interleukin 1 and bacterial endotoxin. Cell based assays using human primary blood cells stimulated with lipopolysaccharide demonstrated that escin dose-dependently inhibits TNF-alpha release (FIG. 1 ). - Murine mast cells stimulated either with IgE and the corresponding antigen respond with the production of several mediators including TNF-alpha which serves as an indicator for the identification of antiallergic substances. Application of escin reduces the release of this mediator in a dose dependent manner. An inhibition of TNF-alpha production of at least 50% was observed at concentrations of 0.31 μM. At a concentration of 30 nM the inhibitory effect was significant. This result indicates that although the inhibitory effect was not as efficient as observed for the control corticosteroid Dexamethasone escin has potent antiallergic properties (
FIG. 2 ). - TNF-induction in mice administration of lipopolysaccharide is a well established model for fast immunological reactions and a model for septic shock. As shown in
FIG. 3 the treatment of mice with 15 mg/kg of escin reduces the TNF-alpha level to 30%. - A patient diagnosed with uticaria pigmentosa, a disease that is characterized by unspecific allergic reactions caused by an overreaction of mast cells. The 49 year old female patient had a history of allergic reactions mainly of the skin and in some cases systemic manifestations that were treated with antihistamines and corticosteroids. Prior treatment a strong allergic reaction was ongoing on the skin of large areas of both legs and hands. The patient reported itching and pain of the skin. Clearly the inflammation of the skin was visible. The following score was used in order to measure the severity of the symptoms: 5=full blown reaction including redness of the skin, itching and pain, open wounds partly visible, 4=reduced redness no itching and light pain, wounds closed, 3=redness still visible, absence of pain, 2=skin colour comparable to unaffected areas, symptoms mild, 1=affected areas indistinguishable from healthy areas, wounds are healing, 0=unaffected healthy skin.
- Both legs of the patient were treated with a gel containing 1.5% escin and some formulation excipients. The score of symptoms for each area was recorded and documented by digital photography (
FIG. 4 ). Treatment for the left leg started atpoint 0. Due to the surprising and fast response the patient requested a treatment of the second leg that was started after one hour. Again the response was very effective. Affected areas on the skin of the left hand served as a control.
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06450109.1 | 2006-08-04 | ||
EP06450109A EP1884245A1 (en) | 2006-08-04 | 2006-08-04 | Use of Escin |
PCT/EP2007/006870 WO2008015007A2 (en) | 2006-08-04 | 2007-08-03 | Use of escin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/006870 A-371-Of-International WO2008015007A2 (en) | 2006-08-04 | 2007-08-03 | Use of escin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/281,635 Continuation US9993512B2 (en) | 2006-08-04 | 2016-09-30 | Use of escin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100227830A1 true US20100227830A1 (en) | 2010-09-09 |
Family
ID=37969918
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/376,419 Abandoned US20100227830A1 (en) | 2006-08-04 | 2007-08-03 | Use of escin |
US15/281,635 Active US9993512B2 (en) | 2006-08-04 | 2016-09-30 | Use of escin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/281,635 Active US9993512B2 (en) | 2006-08-04 | 2016-09-30 | Use of escin |
Country Status (21)
Country | Link |
---|---|
US (2) | US20100227830A1 (en) |
EP (2) | EP1884245A1 (en) |
JP (1) | JP5345933B2 (en) |
KR (1) | KR20090034946A (en) |
CN (1) | CN101500582B (en) |
AU (1) | AU2007280625B2 (en) |
BR (1) | BRPI0715070B8 (en) |
CA (1) | CA2658279C (en) |
DK (1) | DK2046345T3 (en) |
EA (1) | EA015404B1 (en) |
ES (1) | ES2531516T3 (en) |
HR (1) | HRP20141243T1 (en) |
IL (1) | IL196606A (en) |
MX (1) | MX2009000991A (en) |
NZ (1) | NZ574249A (en) |
PL (1) | PL2046345T3 (en) |
PT (1) | PT2046345E (en) |
SI (1) | SI2046345T1 (en) |
UA (1) | UA94954C2 (en) |
WO (1) | WO2008015007A2 (en) |
ZA (1) | ZA200900372B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9463155B2 (en) | 2013-03-15 | 2016-10-11 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US9801900B2 (en) | 2013-11-22 | 2017-10-31 | Mary Kay Inc. | Compositions for sensitive skin |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2445870T3 (en) * | 2008-07-01 | 2014-03-05 | Marinomed Biotechnologie Gmbh | Marine antiallergic biopolymers |
EP2186523A1 (en) * | 2008-11-18 | 2010-05-19 | Marinomed Biotechnologie GmbH | Use of escin for treatment of Type IV hypersensitivity reaction |
ES2346844A1 (en) * | 2010-03-17 | 2010-10-20 | Ricardo Lombardero Calzon | Cream for burns |
WO2012101618A1 (en) | 2011-01-28 | 2012-08-02 | Barcelcom Têxteis S.A. | Compression stockings and tubes with bioactive agents for the treatment of venous insufficiency and varicose veins |
CN104147055A (en) * | 2014-07-08 | 2014-11-19 | 武汉爱民制药有限公司 | Application of lysine aescin and salt thereof in preparing medicaments for treating I-type hypersensitivity |
US20180154777A1 (en) * | 2016-12-02 | 2018-06-07 | Faraday&Future Inc. | Braking torque blending system and method for automatic emergency braking |
IT202100014495A1 (en) * | 2021-06-08 | 2022-12-08 | Neilos S R L | "Composition for use in the prevention and/or treatment of osteoarticular pathologies" |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3402259A1 (en) * | 1984-01-24 | 1985-08-01 | Stephan Dr.med. 3000 Hannover Regöczy | Therapeutically active mixture, in particular for the treatment of infectious diseases in the ear, nose and throat region, chorditis, severe hoarseness and thrombophlebitis |
US6504010B1 (en) * | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6509448B2 (en) * | 1999-06-30 | 2003-01-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6630305B1 (en) * | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6759515B1 (en) * | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6800746B2 (en) * | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6858204B2 (en) * | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6894146B1 (en) * | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6943236B2 (en) * | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7033827B2 (en) * | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
US7049063B2 (en) * | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1676561U (en) | 1954-03-27 | 1954-05-20 | Lutz Kg Maschf Eugen | DEVICE FOR MILLING GROOVES AND THE LIKE. BY MEANS OF A MOTOR MILL. |
DE3445324A1 (en) * | 1984-12-12 | 1986-06-12 | Klinge Pharma GmbH, 8000 München | Pharmaceutical combination with synergistic action |
IT1252866B (en) | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-ACYL DERIVATIVES OF AMINOALCOHOLS WITH POLYCARBOSSYLIC ACIDS FOR THE MODULATION OF MASTOCYTES IN INFLAMMATORY PROCESSES ON A NEURO-IMMUNOGENIC BASIS |
-
2006
- 2006-08-04 EP EP06450109A patent/EP1884245A1/en not_active Withdrawn
-
2007
- 2007-08-03 WO PCT/EP2007/006870 patent/WO2008015007A2/en active Application Filing
- 2007-08-03 BR BRPI0715070A patent/BRPI0715070B8/en not_active IP Right Cessation
- 2007-08-03 PT PT77865392T patent/PT2046345E/en unknown
- 2007-08-03 DK DK07786539.2T patent/DK2046345T3/en active
- 2007-08-03 US US12/376,419 patent/US20100227830A1/en not_active Abandoned
- 2007-08-03 AU AU2007280625A patent/AU2007280625B2/en not_active Ceased
- 2007-08-03 PL PL07786539T patent/PL2046345T3/en unknown
- 2007-08-03 EP EP07786539.2A patent/EP2046345B1/en active Active
- 2007-08-03 CN CN200780029119XA patent/CN101500582B/en active Active
- 2007-08-03 NZ NZ574249A patent/NZ574249A/en not_active IP Right Cessation
- 2007-08-03 KR KR1020097002110A patent/KR20090034946A/en not_active Application Discontinuation
- 2007-08-03 SI SI200731602T patent/SI2046345T1/en unknown
- 2007-08-03 JP JP2009523182A patent/JP5345933B2/en not_active Expired - Fee Related
- 2007-08-03 CA CA2658279A patent/CA2658279C/en active Active
- 2007-08-03 MX MX2009000991A patent/MX2009000991A/en active IP Right Grant
- 2007-08-03 UA UAA200900868A patent/UA94954C2/en unknown
- 2007-08-03 ES ES07786539.2T patent/ES2531516T3/en active Active
- 2007-08-03 EA EA200900261A patent/EA015404B1/en not_active IP Right Cessation
-
2009
- 2009-01-16 ZA ZA2009/00372A patent/ZA200900372B/en unknown
- 2009-01-20 IL IL196606A patent/IL196606A/en not_active IP Right Cessation
-
2014
- 2014-12-22 HR HRP20141243TT patent/HRP20141243T1/en unknown
-
2016
- 2016-09-30 US US15/281,635 patent/US9993512B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3402259A1 (en) * | 1984-01-24 | 1985-08-01 | Stephan Dr.med. 3000 Hannover Regöczy | Therapeutically active mixture, in particular for the treatment of infectious diseases in the ear, nose and throat region, chorditis, severe hoarseness and thrombophlebitis |
US6759515B1 (en) * | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6800746B2 (en) * | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6894146B1 (en) * | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6943236B2 (en) * | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7033827B2 (en) * | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
US7049063B2 (en) * | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
US6504010B1 (en) * | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6509448B2 (en) * | 1999-06-30 | 2003-01-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6858204B2 (en) * | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6630305B1 (en) * | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
Non-Patent Citations (3)
Title |
---|
Regoczy, Stephan; machine translation of DE 3402259 obtained 10 September 2012 * |
Van Cauwenberge, P. et al., Allergy, "Consensus statement on the treatment of allergic rhinitis", 2000, vol. 55, pp.116-134 * |
WebMD, "Decongestants for Sinusitis"; also available at http://www.webmd.com/a-to-z-guides/decongestants-for-sinusitis; last updated 03 August 2010 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9463155B2 (en) | 2013-03-15 | 2016-10-11 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US10299994B2 (en) | 2013-03-15 | 2019-05-28 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US11135139B2 (en) | 2013-03-15 | 2021-10-05 | Belaj Innovations Llc | Cosmetic compositions and uses thereof |
US11723845B2 (en) | 2013-03-15 | 2023-08-15 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US9801900B2 (en) | 2013-11-22 | 2017-10-31 | Mary Kay Inc. | Compositions for sensitive skin |
US10245282B2 (en) | 2013-11-22 | 2019-04-02 | Mary Kay Inc. | Compositions for sensitive skin |
US10736837B2 (en) | 2013-11-22 | 2020-08-11 | Mary Kay Inc. | Compositions for sensitive skin |
US11559480B2 (en) | 2013-11-22 | 2023-01-24 | Mary Kay Inc. | Compositions for sensitive skin |
US11865204B2 (en) | 2013-11-22 | 2024-01-09 | Mary Kay Inc. | Compositions for sensitive skin |
Also Published As
Publication number | Publication date |
---|---|
CN101500582A (en) | 2009-08-05 |
MX2009000991A (en) | 2009-04-16 |
EA200900261A1 (en) | 2009-06-30 |
KR20090034946A (en) | 2009-04-08 |
ES2531516T3 (en) | 2015-03-16 |
IL196606A0 (en) | 2009-11-18 |
AU2007280625A1 (en) | 2008-02-07 |
WO2008015007A3 (en) | 2008-04-03 |
HRP20141243T1 (en) | 2015-02-13 |
SI2046345T1 (en) | 2015-03-31 |
DK2046345T3 (en) | 2015-01-26 |
EP2046345B1 (en) | 2014-12-10 |
JP5345933B2 (en) | 2013-11-20 |
US20170014465A1 (en) | 2017-01-19 |
BRPI0715070B1 (en) | 2021-04-13 |
JP2009545623A (en) | 2009-12-24 |
EP2046345A2 (en) | 2009-04-15 |
PL2046345T3 (en) | 2015-05-29 |
EP1884245A1 (en) | 2008-02-06 |
WO2008015007A2 (en) | 2008-02-07 |
BRPI0715070A2 (en) | 2013-06-25 |
PT2046345E (en) | 2014-12-26 |
IL196606A (en) | 2015-08-31 |
EA015404B1 (en) | 2011-08-30 |
AU2007280625B2 (en) | 2012-05-17 |
NZ574249A (en) | 2011-04-29 |
CA2658279C (en) | 2014-10-28 |
ZA200900372B (en) | 2009-12-30 |
BRPI0715070B8 (en) | 2021-05-25 |
CA2658279A1 (en) | 2008-02-07 |
US9993512B2 (en) | 2018-06-12 |
CN101500582B (en) | 2011-08-24 |
UA94954C2 (en) | 2011-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9993512B2 (en) | Use of escin | |
AU2009266076B2 (en) | Antiallergic marine biopolymers | |
AU2014249456A1 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
KR20150138848A (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
JP2002053485A (en) | Pharmaceutical composition for allergic disease | |
JP2005514414A5 (en) | ||
KR100483539B1 (en) | Composition for preventing or treating atopic dermatitis and process for preparation thereof | |
TWI776234B (en) | Pharmaceutical compositions and uses thereof in treating muscle atrophy | |
US20110224160A1 (en) | Use of Escin for Treatment of Type IV Hypersensitivity Reaction | |
CN113209154B (en) | Application of chicken bone extract in preparation of medicine for preventing and/or treating ulcerative colitis | |
CN106389451B (en) | A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease | |
Shingadiya et al. | Ayurvedic Management of chronic Vitiligo (Shvitra): A case study | |
KR101131108B1 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis containing the membrane-separated extracts of platycodon grandiflorum or platycoside E as an active ingredient | |
KR101308666B1 (en) | Pharmaceutical and food compositions for preventing or treating arthritis comprising extract of tuna eye as active ingredients | |
CN113230255A (en) | Application of apatinib in preparation of medicine for preventing and treating NLRP3 inflammation body related diseases | |
KR20050004846A (en) | Herbal extract for prophylaxis or treatment of inflammatory diseases and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MARINOMED BIOTECHNOLOGIE GMBH, AUSTRIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRASSAUER, ANDREAS;PRIESCHL, EVA;REEL/FRAME:022372/0189 Effective date: 20090119 |
|
AS | Assignment |
Owner name: MARINOMED BIOTECHNOLOGIE GMBH, AUSTRIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ZIPCODE OF THE ASSIGNEE'S ADDRESS FROM 1220 TO 1210 PREVIOUSLY RECORDED ON REEL 022372 FRAME 0189. ASSIGNOR(S) HEREBY CONFIRMS THE EXCLUSIVE RIGHT, TITLE AND INTEREST TO SAID INVENTION IN THE UNITED STATES AND THE LETTERS PATENT APPLICATION;ASSIGNORS:GRASSAUER, ANDREAS;PRIESCHL, EVA;REEL/FRAME:022477/0161 Effective date: 20090119 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |